ASH 2020 | DREAMM-2: Effects of belantamab mafodotin on patient reported outcomes in myeloma
Rakesh Popat, MBBS, MRCP, FRCPath, PhD, University College London Hospitals NHS Foundation Trust, London, UK, shares patient-reported outcomes from the DREAMM-2 study (NCT03525678) of single-agent belantamab mafodotin (belamaf) in relapsed/refractory multiple myeloma. Health-related quality of life (HRQoL) was evaluated with questionnaires to characterize patient’s symptoms, functioning and quality of life. Ophthalmic vision-related questionnaires were also used to assess corneal events. It was found that disease symptoms, functioning and quality of life were all either stable or showed an upward trend as a result of belamaf treatment. Additionally, significant improvements in fatigue, physical functioning and pain were observed. The results also suggest that global health status is maintained despite ocular symptoms. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Honoraria: Takeda, Abbvie, GSK
Consultancy: BMS, Janssen, GSK
